Ph.D. degree from the Max Planck Institute for Biophysical Chemistry, University of Göttingen, Germany. From December 2003 to December 2004, served as a postdoctoral researcher at the Max Planck Institute for Biophysical Chemistry. From July 2006 to November 2013, worked as a researcher at Boston Children's Hospital and Harvard Medical School. From October 2013 to June 2015, he was the research and development director of Biocytogen. From July 2015 to December 2020, he was the vice president of Biocytogen's marketing department. Since December 2020, he has been the deputy general manager of Biocytogen.

Ph.D. degree from the University of Connecticut. In June 2008, served as a postdoctoral researcher at New York University. In July 2014, became an Assistant Professor at the Medical University of South Carolina. From November 2016 to September 2018, served as the Director of Antibody Development at Biocytogen. From September 2018 to November 2020, held the position of CSO at Biocytogen. Since December 2020, currently serving as Deputy General Manager.

Master's degree in International Management from Arizona State University.With over twenty years of financial management experience, served as Finance Operations Manager at Cabletron Systems and Senior Finance Manager at ESS Vialta. He has also worked as Finance Director at ABB Xi'an Power Capacitor Co., Chief Financial Officer at KD BlueSky, Chief Financial Officer at Beijing Century Tianle Business Management Company, and Chief Financial Officer at Anji Julong Management Consulting Partnership Enterprise. From April 2020 to December 2020, he was the Chief Financial Officer at Biocytogen. Since December 2020, he has been serving as the Director of Finance at Biocytogen.

Master's degree in Science from Nankai University. From August 2010 to February 2014, served as an Investment Manager at China National Chemical Corporation (now known as ChemChina Holdings Co., Ltd.). From February 2014 to September 2015, held the position of Senior Investment Manager at China Hi-Tech Investment Group Corporation (now known as China Investment Corporation High Technology Industry Investment Co., Ltd.). From October 2015 to July 2017, worked as a Senior Investment Manager and Investment Deputy Director at ChinaAMC Asset Management Co., Ltd. From July 2017 to December 2020, served as the Assistant to the Chairman at Biocytogen. Since December 2020, have been serving as the Secretary of the Board of Directors. Since July 2021,have also held the position of Deputy General Manager and Secretary of the Board of Directors.

Dirui Li received his Ph.D. from College of Veterinary Medicine, China Agricultural University in 2012 (majoring in veterinary biomedicine) and research focused on infection and Immunology & Recombinant Vaccines; Then he did postdoc research at China Agricultural University and Uppsala University, Sweden. In 2016, he returned to China to join Biocytogen Pharmaceuticals（Beijing）Co., Ltd, successively served as Senior Scientist of Gene Editing Department, Manager of Pharmacological Department and Senior Manager of SD Department, currently served as the head of Pharmacology Department（Beijing/Haimen）, and developed the pharmacological platform (biomarker, drug metabolism, toxicological pathology detection platform) for Pharmacology Department.

Ph.D. degree from China Pharmaceutical University. In 2009, joined Biocytogen and held positions as Molecular Biology Supervisor and Marketing Director. From October 2015 to December 2019, served as a supervisor and Senior Operations Director at Biocytogen in Jiangsu. From January 2020 to December 2020, held the position of Senior Director at the Biocytogen Animal Center. Since December 2020, have been serving as the Senior Director of the Animal Center and Executive Director.

Dr. Yao received his Ph.D. degree in Pharmaceutical Engineering from Tianjin University in 2012. His research interests include protein interactions, high-throughput screening, and mechanisms of antioxidant signaling pathways. In June 2012, he joined Biocytogen. He has led or participated in the development of EGE technology for efficient gene editing, the establishment of gene editing platform for cell lines, the promotion of laboratory automation, and the work related to the development and application of SUPCE technology. Dr. Yao has nearly ten years of experience in gene editing technology development and animal model development. Since November 2022, have been serving as a Supervisor and Director of the Gene Editing Department at Biocytogen.

Dr. Jin received his Bachelors and Ph.D. degrees from the Department of Virology and Molecular Biology atWuhan University. Dr. Jin performed Postdoctoral Research and served as a Research Assistant Professor at the University of Illinois. He also researched human embryonic stem cells at Advanced Cell Technology (ACT). In November 2011, he joined Biocytogen USA and served as the Vice President.